Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II

Wilbert Sybesma, Christine Rohde, Pavol Bardy, Jean-Paul Pirnay, Ian Cooper, Jonathan Caplin, Nina Chanishvili, Aidan Coffey, Daniel De Vos, Amber Hartman Scholz, Shawna McCallin, Hilke Marie Püschner, Roman Pantucek, Rustam Aminov, Jiří Doškař, D. İpek Kurtböke

Research output: Contribution to journalArticleResearchpeer-review

Abstract

This perspective paper follows up on earlier communications on bacteriophage therapy that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a society that is confronted with an ever-increasing number of antibiotic-resistant bacteria, we build on
the previously made recommendations and specifically address how the Nagoya Protocol might impact the further development of bacteriophage therapy. By reviewing a number of recently conducted case studies with bacteriophages involving patients with bacterial infections that could no longer be successfully treated by regular antibiotic therapy, we again stress the urgency and significance of the development of international guidelines and frameworks that might facilitate the legal and effective application of bacteriophage therapy by physicians and the receiving patients. Additionally, we list and comment on several recently started and ongoing clinical studies, including highly desired double-blind placebo-controlled randomized clinical trials. We conclude with an
outlook on how recently developed DNA editing technologies are expected to further control and enhance the efficient application of bacteriophages.
Original languageEnglish
Article number7020035
Pages (from-to)1-23
Number of pages23
JournalAntibiotics
Volume7
Issue number35
DOIs
Publication statusPublished - 23 Apr 2018

Fingerprint

Silk
Bacteriophages
Anti-Bacterial Agents
Bacterial Infections
Randomized Controlled Trials
Communication
Placebos
Guidelines
Technology
Bacteria
Physicians
DNA
Phage Therapy
Therapeutics

Cite this

Sybesma, W., Rohde, C., Bardy, P., Pirnay, J-P., Cooper, I., Caplin, J., ... Kurtböke, D. İ. (2018). Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II. Antibiotics, 7(35), 1-23. [7020035]. https://doi.org/10.3390/antibiotics7020035
Sybesma, Wilbert ; Rohde, Christine ; Bardy, Pavol ; Pirnay, Jean-Paul ; Cooper, Ian ; Caplin, Jonathan ; Chanishvili, Nina ; Coffey, Aidan ; De Vos, Daniel ; Scholz, Amber Hartman ; McCallin, Shawna ; Püschner, Hilke Marie ; Pantucek, Roman ; Aminov, Rustam ; Doškař, Jiří ; Kurtböke, D. İpek. / Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II. In: Antibiotics. 2018 ; Vol. 7, No. 35. pp. 1-23.
@article{ff99ca3ad6374920be5c5c746b216739,
title = "Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II",
abstract = "This perspective paper follows up on earlier communications on bacteriophage therapy that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a society that is confronted with an ever-increasing number of antibiotic-resistant bacteria, we build onthe previously made recommendations and specifically address how the Nagoya Protocol might impact the further development of bacteriophage therapy. By reviewing a number of recently conducted case studies with bacteriophages involving patients with bacterial infections that could no longer be successfully treated by regular antibiotic therapy, we again stress the urgency and significance of the development of international guidelines and frameworks that might facilitate the legal and effective application of bacteriophage therapy by physicians and the receiving patients. Additionally, we list and comment on several recently started and ongoing clinical studies, including highly desired double-blind placebo-controlled randomized clinical trials. We conclude with anoutlook on how recently developed DNA editing technologies are expected to further control and enhance the efficient application of bacteriophages.",
author = "Wilbert Sybesma and Christine Rohde and Pavol Bardy and Jean-Paul Pirnay and Ian Cooper and Jonathan Caplin and Nina Chanishvili and Aidan Coffey and {De Vos}, Daniel and Scholz, {Amber Hartman} and Shawna McCallin and P{\"u}schner, {Hilke Marie} and Roman Pantucek and Rustam Aminov and Jiř{\'i} Doškař and Kurtb{\"o}ke, {D. İpek}",
year = "2018",
month = "4",
day = "23",
doi = "10.3390/antibiotics7020035",
language = "English",
volume = "7",
pages = "1--23",
journal = "Antibiotics",
number = "35",

}

Sybesma, W, Rohde, C, Bardy, P, Pirnay, J-P, Cooper, I, Caplin, J, Chanishvili, N, Coffey, A, De Vos, D, Scholz, AH, McCallin, S, Püschner, HM, Pantucek, R, Aminov, R, Doškař, J & Kurtböke, Dİ 2018, 'Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II' Antibiotics, vol. 7, no. 35, 7020035, pp. 1-23. https://doi.org/10.3390/antibiotics7020035

Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II. / Sybesma, Wilbert; Rohde, Christine; Bardy, Pavol; Pirnay, Jean-Paul; Cooper, Ian; Caplin, Jonathan; Chanishvili, Nina; Coffey, Aidan; De Vos, Daniel; Scholz, Amber Hartman; McCallin, Shawna; Püschner, Hilke Marie; Pantucek, Roman; Aminov, Rustam; Doškař, Jiří; Kurtböke, D. İpek.

In: Antibiotics, Vol. 7, No. 35, 7020035, 23.04.2018, p. 1-23.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Silk Route to the Acceptance and Re-Implementation of Bacteriophage Therapy—Part II

AU - Sybesma, Wilbert

AU - Rohde, Christine

AU - Bardy, Pavol

AU - Pirnay, Jean-Paul

AU - Cooper, Ian

AU - Caplin, Jonathan

AU - Chanishvili, Nina

AU - Coffey, Aidan

AU - De Vos, Daniel

AU - Scholz, Amber Hartman

AU - McCallin, Shawna

AU - Püschner, Hilke Marie

AU - Pantucek, Roman

AU - Aminov, Rustam

AU - Doškař, Jiří

AU - Kurtböke, D. İpek

PY - 2018/4/23

Y1 - 2018/4/23

N2 - This perspective paper follows up on earlier communications on bacteriophage therapy that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a society that is confronted with an ever-increasing number of antibiotic-resistant bacteria, we build onthe previously made recommendations and specifically address how the Nagoya Protocol might impact the further development of bacteriophage therapy. By reviewing a number of recently conducted case studies with bacteriophages involving patients with bacterial infections that could no longer be successfully treated by regular antibiotic therapy, we again stress the urgency and significance of the development of international guidelines and frameworks that might facilitate the legal and effective application of bacteriophage therapy by physicians and the receiving patients. Additionally, we list and comment on several recently started and ongoing clinical studies, including highly desired double-blind placebo-controlled randomized clinical trials. We conclude with anoutlook on how recently developed DNA editing technologies are expected to further control and enhance the efficient application of bacteriophages.

AB - This perspective paper follows up on earlier communications on bacteriophage therapy that we wrote as a multidisciplinary and intercontinental expert-panel when we first met at a bacteriophage conference hosted by the Eliava Institute in Tbilisi, Georgia in 2015. In the context of a society that is confronted with an ever-increasing number of antibiotic-resistant bacteria, we build onthe previously made recommendations and specifically address how the Nagoya Protocol might impact the further development of bacteriophage therapy. By reviewing a number of recently conducted case studies with bacteriophages involving patients with bacterial infections that could no longer be successfully treated by regular antibiotic therapy, we again stress the urgency and significance of the development of international guidelines and frameworks that might facilitate the legal and effective application of bacteriophage therapy by physicians and the receiving patients. Additionally, we list and comment on several recently started and ongoing clinical studies, including highly desired double-blind placebo-controlled randomized clinical trials. We conclude with anoutlook on how recently developed DNA editing technologies are expected to further control and enhance the efficient application of bacteriophages.

U2 - 10.3390/antibiotics7020035

DO - 10.3390/antibiotics7020035

M3 - Article

VL - 7

SP - 1

EP - 23

JO - Antibiotics

T2 - Antibiotics

JF - Antibiotics

IS - 35

M1 - 7020035

ER -